Dr. Powell Discusses CPI-613 in Hematologic Malignancies

Video

In Partnership With:

Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

The well-tolerated toxicities and activity of CPI-613 has prompted further research of the agent as a treatment for patients with myelodysplastic syndromes, Powell notes. Additionally, a second phase I trial will be initiated to explore CPI-613 plus high-dose cytarabine as a treatment for patients with acute myeloid leukemia.

High levels of activity were observed with CPI-613, which is unusual for patients with advanced relapsed or refractory hematologic malignancies, Powell points out. As a result, further investigation into this agent is intriguing.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD